China Manufacturing PMI Rebounds in December, Offering Boost to Economic Growth Outlook 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
South Korea Factory Output Misses Forecasts in November Amid Ongoing Economic Uncertainty 
Citi Forecasts a Volatile but Ongoing Bull Market for S&P 500 in 2026 
Asian Currencies Trade Flat as Dollar Weakens in Thin New Year Trading 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Trump Delays Tariff Increases on Furniture and Cabinets for One More Year 
USDA $12 Billion Farm Aid Program Draws Mixed Reactions from Row Crop Farmers 
South Korea Factory Activity Returns to Growth in December on Export Rebound 
U.S. Stock Index Futures Steady as Markets Await Fed Policy Clues in Holiday-Thinned Trade 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
